Showing 1 - 6 results of 6 for search 'Andreas H. Scheel', query time: 0.03s Refine Results
  1. 1
    Physical basis of the ‘magnification rule’ for standardized Immunohistochemical scoring of HER2 in breast and gastric cancer

    Physical basis of the ‘magnification rule’ for standardized Immunohistochemical scoring of HER2 in breast and gastric cancer by Andreas H. Scheel, Frédérique Penault-Llorca, Wedad Hanna, Gustavo Baretton, Peter Middel, Judith Burchhardt, Manfred Hofmann, Bharat Jasani, Josef Rüschoff

    Published 2018-03-01
    Get full text
    Article
  2. 2
    Tumour area infiltration and cell count in endoscopic biopsies of therapy-naive upper GI tract carcinomas by QuPath analysis: implications for predictive biomarker testing

    Tumour area infiltration and cell count in endoscopic biopsies of therapy-naive upper GI tract carcinomas by QuPath analysis: implications for predictive biomarker testing by Andreas H. Scheel, Hannah Lamberty, Yuri Tolkach, Florian Gebauer, Birgid Schoemig-Markiefka, Thomas Zander, Reinhard Buettner, Josef Rueschoff, Christiane Josephine Bruns, Wolfgang Schroeder, Alexander Quaas

    Published 2023-10-01
    Get full text
    Article
  3. 3
    High-Throughput Profiling of Colorectal Cancer Liver Metastases Reveals Intra- and Inter-Patient Heterogeneity in the EGFR and WNT Pathways Associated with Clinical Outcome

    High-Throughput Profiling of Colorectal Cancer Liver Metastases Reveals Intra- and Inter-Patient Heterogeneity in the EGFR and WNT Pathways Associated with Clinical Outcome by Kerstin Menck, Darius Wlochowitz, Astrid Wachter, Lena-Christin Conradi, Alexander Wolff, Andreas H. Scheel, Ulrike Korf, Stefan Wiemann, Hans-Ulrich Schildhaus, Hanibal Bohnenberger, Edgar Wingender, Tobias Pukrop, Kia Homayounfar, Tim Beißbarth, Annalen Bleckmann

    Published 2022-04-01
    Get full text
    Article
  4. 4
    ALK G1269A mutation as a potential mechanism of acquired resistance to crizotinib in an ALK-rearranged inflammatory myofibroblastic tumor

    ALK G1269A mutation as a potential mechanism of acquired resistance to crizotinib in an ALK-rearranged inflammatory myofibroblastic tumor by Sebastian Y. F. Michels, Andreas H. Scheel, Thomas Wündisch, Johannes M. Heuckmann, Roopika Menon, Michael Puesken, Carsten Kobe, Helen Pasternack, Carina Heydt, Matthias Scheffler, Rieke Fischer, Anne M. Schultheis, Sabine Merkelbach-Bruse, Lukas Heukamp, Reinhard Büttner, Jürgen Wolf

    Published 2017-03-01
    Get full text
    Article
  5. 5
    Oncogenic KRAS Impairs EGFR Antibodies' Efficiency by C/EBPβ-Dependent Suppression of EGFR Expression

    Oncogenic KRAS Impairs EGFR Antibodies' Efficiency by C/EBPβ-Dependent Suppression of EGFR Expression by Stefanie Derer, Sven Berger, Martin Schlaeth, Tanja Schneider-Merck, Katja Klausz, Stefan Lohse, Marije B. Overdijk, Michael Dechant, Christian Kellner, Iris Nagelmeier, Andreas H. Scheel, Jeroen J. Lammerts van Bueren, Jan G.J. van de Winkel, Paul W.H.I. Parren, Matthias Peipp, Thomas Valerius

    Published 2012-03-01
    Get full text
    Article
  6. 6
    Somatic rearrangements causing oncogenic ectodomain deletions of FGFR1 in squamous cell lung cancer

    Somatic rearrangements causing oncogenic ectodomain deletions of FGFR1 in squamous cell lung cancer by Florian Malchers, Lucia Nogova, Martijn H.A. van Attekum, Lukas Maas, Johannes Brägelmann, Christoph Bartenhagen, Luc Girard, Graziella Bosco, Ilona Dahmen, Sebastian Michels, Clare E. Weeden, Andreas H. Scheel, Lydia Meder, Kristina Golfmann, Philipp Schuldt, Janna Siemanowski, Jan Rehker, Sabine Merkelbach-Bruse, Roopika Menon, Oliver Gautschi, Johannes M. Heuckmann, Elisabeth Brambilla, Marie-Liesse Asselin-Labat, Thorsten Persigehl, John D. Minna, Henning Walczak, Roland T. Ullrich, Matthias Fischer, Hans Christian Reinhardt, Jürgen Wolf, Reinhard Büttner, Martin Peifer, Julie George, Roman K. Thomas

    Published 2023-11-01
    Get full text
    Article

Search Tools: